INT132718

Context Info Confidence 0.16 First Reported 2005 Last Reported 2009 Negated 2 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 1.36 Pain Relevance 0.09

cell differentiation (PAX5) nucleus (PAX5) DNA binding (PAX5)

PAX5 (Homo sapiens)

Pain Link Frequency Relevance Heat abdominal pain 1 90.24 Crohn's disease 3 5.00 cytokine 1 5.00 Angina 1 5.00 Inflammation 1 5.00 Pain 1 5.00 backache 1 5.00 addiction 1 5.00 Osteoarthritis 1 5.00

Disease Link Frequency Relevance Heat Hypercalcemia 22 99.60 Gastroesophageal Reflux Disease 1 91.20 Abdominal Pain 1 90.24 Disorder Of Lipid Metabolism 5 77.08 Mycobacterial Infection 81 74.00 Infection 11 59.44 Hypocalcemia 1 42.64 Laboratory Infection 1 33.20 Disease 8 32.64 Sprains And Strains 18 31.88

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

In conclusion, D-003 (10 mg/day) reduced urinary excretion of tDPD/Cr, a bone resorption marker and did not change serum BSAP, a bone formation marker, while it lowered cholesterol in study patients.

Neg (not) Regulation (change) of BSAP associated with hypercalcemia

1) Confidence 0.16 Published 2005 Journal Int J Clin Pharmacol Res Section Abstract Doc Link 16402634 Disease Relevance 0.71 Pain Relevance 0.09

Inversely, and based on our luciferase reporter gene assays, the loss of the potential PAX5, AHR and ARNT transcription factor binding sites predicted for the IRGM variant ?

Regulation (sites) of PAX5

2) Confidence 0.09 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2735778 Disease Relevance 0.32 Pain Relevance 0

Serum BSAP levels did not change during the first month after dosing, and then gradually decreased in all treatment groups to about 60% below baseline values.

Neg (not) Regulation (change) of BSAP

3) Confidence 0.07 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.